JPWO2023238845A1 - - Google Patents
Info
- Publication number
- JPWO2023238845A1 JPWO2023238845A1 JP2024526444A JP2024526444A JPWO2023238845A1 JP WO2023238845 A1 JPWO2023238845 A1 JP WO2023238845A1 JP 2024526444 A JP2024526444 A JP 2024526444A JP 2024526444 A JP2024526444 A JP 2024526444A JP WO2023238845 A1 JPWO2023238845 A1 JP WO2023238845A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022092195 | 2022-06-07 | ||
| PCT/JP2023/020932 WO2023238845A1 (ja) | 2022-06-07 | 2023-06-06 | 加齢疾患の治療又は予防のための抗インテグリンα１１抗体を含む医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2023238845A1 true JPWO2023238845A1 (https=) | 2023-12-14 |
Family
ID=89118457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024526444A Pending JPWO2023238845A1 (https=) | 2022-06-07 | 2023-06-06 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250163158A1 (https=) |
| EP (1) | EP4537841A1 (https=) |
| JP (1) | JPWO2023238845A1 (https=) |
| WO (1) | WO2023238845A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119632990B (zh) * | 2024-12-13 | 2025-11-18 | 温州医科大学 | 腔肠素在制备治疗心脏有关疾病的药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2709411A1 (en) * | 2006-12-18 | 2008-06-26 | Cartela R&D Ab | Binding agents to the integrin alpha-11 subunit, and uses thereof |
| TW201333034A (zh) | 2011-12-22 | 2013-08-16 | Astellas Pharma Inc | 新穎抗人類ｃｔｇｆ抗體 |
| EP3593134A1 (en) * | 2017-03-09 | 2020-01-15 | Cleara Biotech B.V. | Biomarkers for cellular senescence |
| EP3421607A1 (en) * | 2017-06-29 | 2019-01-02 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Identification and elimination of damaged and/or senescent cells |
| CA2985274A1 (en) | 2017-11-10 | 2019-05-10 | Johan Fransson | Integrin antibodies and uses thereof |
| EP3517549A1 (en) | 2018-01-24 | 2019-07-31 | Bergen Teknologioverforing AS | Antibody against alpha-11 integrin and its use |
| EP3760722A4 (en) | 2018-03-01 | 2021-11-24 | Hiroshima University | MONOCLONAL ANTI-INTEGRIN ALPHA11 ANTIBODY AND USES THEREOF |
| WO2021127500A1 (en) * | 2019-12-20 | 2021-06-24 | Momenta Pharmaceuticals, Inc. | Antibodies against integrin alpha 11 beta 1 |
-
2023
- 2023-06-06 JP JP2024526444A patent/JPWO2023238845A1/ja active Pending
- 2023-06-06 US US18/872,623 patent/US20250163158A1/en active Pending
- 2023-06-06 EP EP23819825.3A patent/EP4537841A1/en active Pending
- 2023-06-06 WO PCT/JP2023/020932 patent/WO2023238845A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4537841A1 (en) | 2025-04-16 |
| US20250163158A1 (en) | 2025-05-22 |
| WO2023238845A1 (ja) | 2023-12-14 |